Lupus nephritis (LN) is the most common complication of systemic lupus erythematosus (SLE), with up to 70 % of pediatric SLE patients experiencing kidney involvement, and LN also aggravates the progression of SLE [1]. Hyperlipidemia, in some cases of LN, may manifest in the early stages of renal injury [2]. LN patients with suboptimal lipid control tend to have more significant kidney damage progression [3]. In pediatric patients with SLE, approximately 63 % exhibit abnormal lipid metabolism, primarily characterized by elevated triglycerides (TG) [4].
